ROCKVILLE, Md., April 12, 2011 /PRNewswire/ — Neuralstem, Inc.
(NYSE Amex:
CUR) announced that Eva Feldman, M.D., Ph.D., Principal
Investigator of the Phase I safety trial of Neuralstem’s human
spinal cord stem cells (HSSC) in amyotrophic lateral sclerosis (ALS
or Lou Gehrig’s disease), and unpaid Neuralstem consultant,
presented interim safety data on the first nine patients. Dr.
Feldman reported yesterday at the American Academy of Neurology
(AAN American Academy of Neurology (AAN) Annual Meeting (http://www.aan.com/go/am11)
that all nine ALS patients remain alive and that there were no
unresolved serious adverse reactions related to surgery. Of the
three ambulatory patients who were treated, all remain ambulatory
with no serious adverse events secondary to surgery.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)
“We are delighted. This data demonstrates it is feasible to
transplant stem cells directly into the spinal cord of patients
with ALS using the procedure and device we developed for this
trial,” commented Dr. Feldman, who is also Director of the A.
Alfred Taubman Medical Research Institute and Director of Research
of the ALS Clinic at the University of Michigan Health System.
“This groundbreaking work has never been done before, and we are
thrilled that it can be done safely.”
In this group of nine male patients, ranging in age from
37-to-66 years, with ALS duration at the time of surgery
ranging from 1-to-12 years, the first six were non-ambulatory with
complete paralysis. Of these, four out of six experienced transient
neuropathic pain in the spinal dermatomes near the injected area
within 24 hours of the procedure, which resolved with no treatment.
Three out of the six experienced adverse events secondary to
immunosupp
‘/>”/>
SOURCE
